ÄÐÈ˹¬µî

Careers Contact Locations

ÄÐÈ˹¬µî.

  • ÄÐÈ˹¬µî
  • Who We Are
    • Our Vision
    • Our History
    • Our Leadership
  • What We Do
    • Overview
    • Our Products
    • Our Solutions
    • Our Technology
    • Our Research
    • Our Diagnostics
  • News & Media
    • Press Releases
    • Announcements
    • Events
    • Presentations
  • Investors
    • Overview
    • News / Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Careers
  • Contact
  • Locations

Press Releases

News & Media

News & Media

  • Press Releases
  • Announcements
  • Events
  • Presentations

JAPAN’S MHLW APPROVES PFIZER AND OPKO’S NGENLA® (SOMATROGON), A NEW LONG-ACTING TREATMENT FOR PEDIATRIC GROWTH HORMONE DEFICIENCY

Jan 20, 2022

Sema4 to Acquire GeneDx, Strengthening its Market-Leading AI-Driven Genomic and Clinical Data Platform

Jan 18, 2022

ÄÐÈ˹¬µî to Participate in the 40th Annual J.P. Morgan Healthcare Conference

Jan 5, 2022

ÄÐÈ˹¬µî Announces Topline Results from Phase 2 Trial Evaluating RAYALDEE to Treat Symptomatic COVID-19 Outpatients

Dec 23, 2021

ÄÐÈ˹¬µî Receives U.S. FDA Approval for the 4Kscore® Test

Dec 8, 2021

ÄÐÈ˹¬µî Announces the Passing of Director Dr. Richard Lerner

Dec 6, 2021

BioReference Laboratories Announces Readiness for COVID-19 Testing if the Omicron COVID-19 Variant Emerges in The U.S.

Nov 29, 2021

ÄÐÈ˹¬µî Announces Participation in Piper Sandler 33rd Annual Virtual Healthcare Conference

Nov 29, 2021

ÄÐÈ˹¬µî Reports 2021 Third Quarter Business Highlights and Financial Results

Oct 28, 2021

ÄÐÈ˹¬µî to Report Third Quarter 2021 Financial Results on October 28, 2021

Oct 25, 2021
RSS
  • Prev
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • ...49
    Next

    OPKO HEALTH, INC.
    4400 Biscayne Boulevard
    Miami, FL 33137

    305-575-4100
    contact@opko.com

    © 2023 ÄÐÈ˹¬µî. All Rights Reserved.
    Privacy Policy Governance Terms of Use Sitemap